Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Trial Profile

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Linagliptin (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2016 The inclusion criteria has been expanded to include patients with minimum age of 18 years.
    • 01 Dec 2015 Number of treatment arms changed from 1 to 2, Linagliptin control group was added to treatment arms. Hence, study design changed from single group assignment to parallel, patient number also changed from 8 to 18, according to ClinicalTrials.gov record.
    • 01 Dec 2015 Planned number of patients changed from 8 to 18, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top